SCHEMBL15260454

SCHEMBL15260454

Cc1c(Oc2ccc(C=O)cc2)ncnc1OC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.74

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 17/20 0.74
▸ PIK3CD O00329 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15260169 0.87 GPR119 (0.59) GPR119
SCHEMBL15260371 0.85 GPR119 (1.00) GPR119
SCHEMBL16927311 0.85 GPR119 (1.00) GPR119
SCHEMBL15260372 0.85 GPR119 (1.00) GPR119
SCHEMBL12241532 0.84 GPR119 (0.63) GPR119
SCHEMBL224172 0.82 GPR119 (0.63) GPR119
SCHEMBL2729174 0.81 GPR119 (0.60) GPR119PIK3CD
SCHEMBL2718734 0.81 GPR119 (0.60) GPR119PIK3CD
SCHEMBL2730570 0.81 GPR119 (0.60) GPR119PIK3CD
SCHEMBL2718736 0.81 GPR119 (0.60) GPR119PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2625177-B1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LTD (IN) 2015-07-29 — — EP disclosed
US-8785463-B2 GPR 119 agonists CADILA HEALTHCARE LIMITED (IN) 2014-07-22 — — US disclosed
US-20130252980-A1 NOVEL GPR 119 AGONISTS CADILA HEALTHCARE LIMITED (IN) 2013-09-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252980-A1 NOVEL GPR 119 AGONISTS GPR119, GPR27, GPR4 GPR119 1/4885PIK3CD 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback